SCHEMBL22608236

SCHEMBL22608236

O=C(OC(=O)C(F)(F)F)c1[nH]nnc1-c1ccc(-c2ccc(Cl)cc2)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MARS1 P56192 2/20 0.39
ALPL P05186 3/20 0.34
MAPT P10636 1/20 0.34
SRD5A2 P31213 1/20 0.33
ALOX5AP P20292 1/20 0.33
GYS1 P13807 1/20 0.33
CNR1 P21554 8/20 0.32
CNR2 P34972 5/20 0.32
DGAT1 O75907 1/20 0.32
SOAT1 P35610 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22807422 0.91 MARS1 (0.41) MARS1
SCHEMBL22608390 0.87 MAPT (0.36) ALPLMAPTGYS1
SCHEMBL22608229 0.83 MARS1 (0.36) MARS1ALPLMAPTSRD5A2
Trifluoroacetic Acid SCHEMBL29490710 0.83 MARS1 (0.46) MARS1ALPLSRD5A2CNR1DGAT1
Trifluoroacetic Acid SCHEMBL22608233 0.83 MARS1 (0.46) MARS1ALPLSRD5A2CNR1DGAT1
SCHEMBL29852165 0.80 MARS1 (0.52) MARS1ALPLSRD5A2CNR1
SCHEMBL22816678 0.80 MARS1 (0.52) MARS1ALPLSRD5A2CNR1
SCHEMBL23484568 0.77 MARS1 (0.48) MARS1
Trifluoroacetic Acid SCHEMBL22807420 0.77 MARS1 (0.46) MARS1
Trifluoroacetic Acid SCHEMBL29490729 0.77 MARS1 (0.46) MARS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
EP-3986863-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BioMarin Pharmaceutical Inc. (US) 2022-04-27 EP disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed
EP-3732167-A2 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BioMarin Pharmaceutical Inc. (US) 2020-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT MARS1 1901/4885ALPL 728/4885MAPT 1215/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT MARS1 1818/4885ALPL 807/4885MAPT 1082/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT MARS1 1901/4885ALPL 728/4885MAPT 1215/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT MARS1 1901/4885ALPL 728/4885MAPT 1215/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT MARS1 1901/4885ALPL 728/4885MAPT 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.